Ionis Pharmaceuticals (Nasdaq: IONS) has completed enrollment in the pivotal cohort of its global Phase 3 REVEAL study evaluating obudanersen ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE